An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Recruiting now · Phase 3
Conditions studied: Type 1 Diabetes, Kidney Transplant
In brief
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Key facts
- Study ID
- NCT06832410
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 10
- Starts
- 2025-03-31
- Expected to finish
- 2027-09-17
- Last updated by the study team
- 2026-03-23
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Perelman Center for Advanced Medicine - Endocrinology — Philadelphia, Pennsylvania, United States (enrolling)
- Montefiore Clinical and Translational Research Center - Endocrinology — Pittsburgh, Pennsylvania, United States (enrolling)
- UW University Hospital - Endocrinology — Madison, Wisconsin, United States (enrolling)
- Toronto General Hospital - Endocrinology — Toronto, Canada (enrolling)
- Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre — Vancouver, Canada (enrolling)
- King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology — Riyadh, Saudi Arabia (enrolling)
- King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology — Riyadh, Saudi Arabia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.